Awards
CIRM awards $3.9M to Regencor for development of delivery of FSTL1
San Carlos, CA. - November 24, 2021 - Regencor announced today that the Application Review Subcommittee of the California Institute for Regenerative Medicine (CIRM) awarded Regencor $3.9M for the performance of IND-enabling studies of their proprietary cardio-regenerative recombinant human protein, FSTL1. Continue Reading...
The Global Health & Pharma Biotechnology Awards 2021
Regencor wins, for the second year in a row, The Global Health & Pharma Biotechnology Awards 2021 as a "Leading Innovator in Cardiac Muscle Regeneration". Check out the article on the GHP website
REGENCOR awarded AMGEN Golden Ticket 2019
On June 25, 2019 Amgen and MBC BioLabs announced in San Francisco that Regencor has been awarded an Amgen Golden Ticket to MBC BioLabs. The company receives priority admission or renewal for one year of lab bench space and access to core facilities at the MBC BioLabs life sciences incubator, as well as connections to Amgen’s scientific and business leaders to help advance their scientific program
